Geneva Capital Management LLC Has $68.10 Million Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Geneva Capital Management LLC lessened its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 4.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 170,425 shares of the biotechnology company’s stock after selling 8,621 shares during the quarter. Geneva Capital Management LLC’s holdings in Axon Enterprise were worth $68,102,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. PFG Investments LLC increased its holdings in shares of Axon Enterprise by 0.6% in the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after purchasing an additional 25 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its position in Axon Enterprise by 1.6% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 26 shares during the last quarter. Mather Group LLC. increased its stake in shares of Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 27 shares during the period. CWM LLC raised its position in shares of Axon Enterprise by 1.3% during the third quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock worth $1,141,000 after acquiring an additional 36 shares during the last quarter. Finally, SPC Financial Inc. boosted its holdings in Axon Enterprise by 2.2% in the third quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 38 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Craig Hallum boosted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Barclays increased their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Bank of America assumed coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Finally, Needham & Company LLC lifted their price objective on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $427.83.

Insider Buying and Selling

In other Axon Enterprise news, Director Julie A. Cullivan sold 900 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the transaction, the director now owns 3,653 shares of the company’s stock, valued at $1,291,445.09. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Axon Enterprise news, President Joshua Isner sold 25,811 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the transaction, the president now owns 228,166 shares in the company, valued at $82,103,253.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the transaction, the director now directly owns 3,653 shares in the company, valued at approximately $1,291,445.09. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 369,172 shares of company stock worth $136,270,842. Insiders own 5.70% of the company’s stock.

Axon Enterprise Trading Down 3.4 %

Axon Enterprise stock opened at $595.18 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The firm has a 50-day moving average of $423.98 and a 200-day moving average of $351.79. The company has a market cap of $45.38 billion, a price-to-earnings ratio of 153.79, a P/E/G ratio of 15.47 and a beta of 0.94. Axon Enterprise, Inc. has a one year low of $216.73 and a one year high of $624.84.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.